Novel formulations and methods for treating dermatological disorders or diseases

Abstract

The present invention provides compositions and methods for treating a dermatological disorder or disease.

1 . A pharmaceutically acceptable composition for treating or ameliorating a dermatological disorder or disease, wherein said composition comprises a pharmaceutically acceptable excipient and at least one component selected from the group consisting of:
 (a) a metered amount of a volatile anesthetic dissolved in a solution in an amount effective to treat said dermatological disorder or disease, wherein said solution further comprises at least one extractive solvent in an amount effective to reduce volatility of said volatile anesthetic, wherein said solution is a component of an emulsion;   (b) a metered amount of a liposome suspension comprising a volatile anesthetic in an amount effective to treat said dermatological disorder or disease;   (c) a metered amount of a volatile anesthetic dissolved in a solution in an amount effective to treat said dermatological disorder or disease, wherein said solution further comprises at least one extractive solvent in an amount effective to reduce volatility of said volatile anesthetic, wherein said composition further comprises a solubilizing agent;   (d) a metered amount of a micro-droplet suspension, wherein said micro-droplet suspension comprises a sphere of a volatile anesthetic in an amount effective to treat said dermatological disorder or disease, wherein said sphere is surrounded by a stabilizing layer of a phospholipid;   and any combinations thereof.   
     
     
         2 . The composition of  claim 1 , wherein said at least one extractive solvent is selected from the group consisting of dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), dimethylformamide, dimethylacetamide, dimethylisosorbide, ethanol, propanol, PEG-400, PEG-300, diethylene glycol monoethyl ether, isopropanol, and any combinations thereof. 
     
     
         3 . The composition of  claim 1 , wherein said composition is formulated for an administration route selected from the group consisting of topical, transdermal, mucosal, rectal, vaginal, and any combinations thereof. 
     
     
         4 . The composition of  claim 1 , wherein said volatile anesthetic is selected from the group consisting of isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon and any mixtures thereof. 
     
     
         5 . The composition of  claim 1 , wherein said dermatological disorder or disease is selected from the group consisting of eczema, dermatitis, psoriasis, itching, urticaria, allodynia, dry skin, sunburn, topical bacterial infections, topical fungal infections, hidradenitis suppurativa, scab healing, scar growth, development or emergence of moles, pimples, ingrown hair, punctate palmoplantar keratoderma, dandruff and any combinations thereof. 
     
     
         6 - 10 . (canceled)